References
- Kumar A, Sharma A, Duseja A, Das A, Dhiman RK, Chawla YK, et al. Patients with nonalcoholic fatty liver disease (NAFDL) have higher oxidative stress in comparison to chronic viral hepatitis. J Clin Exp Hepatol. 2012;3:12-8.
- Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, Feng Y. The role of oxidative stress and antioxidants in liver diseases. Int J Mol Sci. 2015;16:26087-124. https://doi.org/10.3390/ijms161125942
- Griffith CM, Schenker S. The role of nutritional therapy in alcoholic liver disease. Alcohol Res Health. 2006;29:296-306.
- Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC. McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-9. https://doi.org/10.1016/S0016-5085(99)70506-8
- Marchesini G, Brizi M, Morselli-Labate AM, Buqianesi E, McCullough AJ, Forlani G. Association of nonalcoholic fatty liver diseases with insulin resistance. Am J Med. 1999;107:450-5. https://doi.org/10.1016/S0002-9343(99)00271-5
- Sato K, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, et al. Vitamin E has a beneficial effects on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition. 2015;31:323-930.
- Rouabhia S, Milic N, Abenavoli L. Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism. Expert Rev Gastroenterol Hepatol. 2014;8:343-9. https://doi.org/10.1586/17474124.2014.894880
- Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Anqelico F. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2015;47:4-11. https://doi.org/10.1016/j.dld.2014.07.170
- Di Minno MN, Russolilo A, Lupoli R, Ambrosino P, Di Minno A, Tarantino G. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol. 2012;18:5839-47. https://doi.org/10.3748/wjg.v18.i41.5839
- Heo J. Translated Dongeuibogam. 1st ed. Seoul: Bubinmunwha; 1999.
- Lee DH, Kang SS, Chang IM, Mar W. Detection of anti-inflammatory agents from natural products as inhibitors of cyclooxygenase I and II. Nat Prod Sci. 1997;3:19-28.
- Murata S, Ogawa K, Matsuzaka T, Chiba M, Nakayama K, Iwasaki K, et al. 1,8-Cineole ameliorates steatosis of pten liver specific KO mice via Akt inactivation. Int J Mol Sci. 2015;16:12051-63. https://doi.org/10.3390/ijms160612051
- Viollet B, Foretz M, Guigas B, Horman S, Dentin R, Bertrand L, et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hapatic disorders. J Physiol. 2006;574:41-53. https://doi.org/10.1113/jphysiol.2006.108506
- Smith BK, Marcinko K, Desjardins EM, Lally JS, Ford RJ, et al. Treatment of nonalcoholic fatty liver disease: role of AMPK. Am J Physiol Endocrinol Metab. 2016;311:730-40. https://doi.org/10.1152/ajpendo.00225.2016
- Kohijima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med. 2008;21:507-11.
- Thomson DM, Winder WW. AMP-activated protein kinase control of fat metabolism in skeletal muscle. Acta Physiol. 2009;196:147-54. https://doi.org/10.1111/j.1748-1716.2009.01973.x
- Tolman KG, Dalpiaz AS. Treatment of non-alcoholic fatty liver disease. Ther Clin Risk Manaq. 2007;3:1153-63.
- Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol. 2012;18:727-35. https://doi.org/10.3748/wjg.v18.i8.727
- Lim DW, Kim H, Park JY, Kim JE, Moon JY, Park SD, Park WH. Amomum cardamomum L. ethyl acetate fraction protects against carbon tetrachloride-induced liver injury via an antioxidant mechanism in rats. BMC Complement Altern Med. 2016;16:155. https://doi.org/10.1186/s12906-016-1121-1
- Lim DW, Bose S, Wang JH, Choi HS, Kim YM, Chin YW, et al. Mofied SJH alleviates FFAs-induced hapatic steatosis through leptin signaling pathways. Sci Rep. 2017;7:45425. https://doi.org/10.1038/srep45425
- Min KJ, Cho KH, Kwon TK. The effects of oxidized low density lipoprotein (oxLDL)-induced heme oxygenase-1 on LPS-induced inflammation in RAW 264.7 macrophage cells. Cell Signal. 2012;24:1215-21. https://doi.org/10.1016/j.cellsig.2012.02.001
- Bekkering S, Quintin J, Joosten LA, van der Meer JW, Netea MG, Riksen NP. Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. Arterioscler Thromb Vasc Biol. 2014;34:1731-8. https://doi.org/10.1161/ATVBAHA.114.303887
- Beltowski J. Statins and modulation of oxidative stress. Toxicol Mech Methods. 2005;15:61-92. https://doi.org/10.1080/15376520590918766
- Leamy AK, Eqnatchik RA, Young JD. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res. 2013;52:165-74. https://doi.org/10.1016/j.plipres.2012.10.004
- Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008;585:325-37. https://doi.org/10.1016/j.ejphar.2008.03.008
- Sultana B, Anwar F. Flavonols (kaempeferol, quercetin, myricetin) contents of selected fruits, vegetables and medicinal plants. Food Chem. 2008;108:879-84. https://doi.org/10.1016/j.foodchem.2007.11.053
- Lee KG, Shibamoto T, Takeoka GR, Lee SE, Kim JH, Park BS. Inhibitory effects of plant-derived flavonoids and phenolic acids on malonaldehyde formation from ethyl arachidonate. J Agric Food Chem. 2003;51:7203-7. https://doi.org/10.1021/jf0345447
- Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125-31. https://doi.org/10.1172/JCI0215593
- Kim JE. Tribulus terrestris suppresses the lipopolys accharide-induced inflammatory reaction in RAW264.7 macrophages through heme oxygenase-1 expression. Korean J Oriental Physiology & Pathology. 2014;28:63-8.
- Sikora JP, Chlebna-Sokol D, Krzyanska-Oberbek A. Proinflammatory cytokine (IL-6, IL-8), cytokine inhibitors (IL-6sR, STNFRII) and anti-inflammatory cytokines (IL-10, IL-13) in the pathogenesis of sepsis in newborns and infants. Arch Immunol Exp. 2001;49:399-404.
Cited by
- 사염화탄소로 유발된 산화적 손상에 대한 황칠나무 잎 추출물의 간세포 보호 효과 vol.30, pp.4, 2017, https://doi.org/10.5352/jls.2020.30.4.370